Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENXBIO Inc.RGNX · Entity 2211 | Chief Business Officer | January 04, 2017 | January 06, 2017 |
| Tenaya Therapeutics, Inc.TNYA · Entity 6506 | Director · Chief Executive Officer | September 10, 2026 | September 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENXBIO Inc.
Report date January 04, 2017 · Filed January 06, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.50 · Expires 2027-01-03 | Direct | 25,200 |
Reported balance
After 2017-01-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-04 · Grant · Acquired 25,200 · Balance 25,200 F1: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following 1/4/2018 while the optionee provides continuous service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following 1/4/2018 while the optionee provides continuous service to the Issuer.
Tenaya Therapeutics, Inc.
Report date September 10, 2026 · Filed September 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 539,782 |
Reported balance
After 2026-09-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-10 · Grant · Acquired 122,000 · Balance 539,782 F1: Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock. F2: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. Amended and Restated 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on February 15, 2027, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested. F3: Includes 384,069 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.65 · Expires 2036-09-09 | Direct | 732,500 |
Reported balance
After 2026-09-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-10 · Grant · Acquired 732,500 · Balance 732,500 F4: Option granted pursuant to the Tenaya Therapeutics, Inc. Amended and Restated 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock.
F2: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. Amended and Restated 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on February 15, 2027, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested.
F3: Includes 384,069 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
F4: Option granted pursuant to the Tenaya Therapeutics, Inc. Amended and Restated 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2026 Filed Sep 12, 2026 00:10 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 732,500 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001193125-26-389563 · ownership.xml · derivative · entry 2 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 732,500 Underlying: Common Stock · 732,500 shares Expires 2036-09-09 F4 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. Amended and Restated 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested. Read SEC document |
| September 10, 2026 Filed Sep 12, 2026 00:10 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantCommon Stock | 122,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-389563 · ownership.xml · nonDerivative · entry 1 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 539,782 F1 · security: Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. Amended and Restated 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on February 15, 2027, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested. F3 · balance_after: Includes 384,069 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 00:50 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 7,406 | $0.71 | $5,256.04 |
DisclosureSEC source: 0001193125-26-354518 · ownership.xml · nonDerivative · entry 4 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 417,782 F8 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 3, 2026. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $.6820 to $.7253. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F9 · balance_after: Includes 262,069 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 00:50 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 5,020 | $0.71 | $3,562.69 |
DisclosureSEC source: 0001193125-26-354518 · ownership.xml · nonDerivative · entry 3 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 425,188 F6 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 6, 2025. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $.6820 to $.7253. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F7 · balance_after: Includes 281,894 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 00:50 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 3,969 | $0.71 | $2,817.20 |
DisclosureSEC source: 0001193125-26-354518 · ownership.xml · nonDerivative · entry 2 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 430,208 F4 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $.6820 to $.7253. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F5 · balance_after: Includes 295,331 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 00:50 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 5,837 | $0.71 | $4,142.52 |
DisclosureSEC source: 0001193125-26-354518 · ownership.xml · nonDerivative · entry 1 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434,177 F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $.6820 to $.7253. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 305,956 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 18, 2026 Filed May 19, 2026 23:09 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 3,390 | $0.79 | $2,689.63 |
DisclosureSEC source: 0001193125-26-231324 · ownership.xml · nonDerivative · entry 1 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 440,014 F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 6, 2025. F2 · balance_after: Includes 321,581 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 00:14 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 5,032 | $0.64 | $3,235.58 |
DisclosureSEC source: 0001193125-26-055442 · ownership.xml · nonDerivative · entry 3 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 443,404 F6 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 6, 2025. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.6075 to $0.671. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F7 · balance_after: Includes 330,187 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 00:14 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 3,979 | $0.64 | $2,558.89 |
DisclosureSEC source: 0001193125-26-055442 · ownership.xml · nonDerivative · entry 2 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 448,436 F4 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.6075 to $0.671. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F5 · balance_after: Includes 343,625 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 00:14 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 5,851 | $0.64 | $3,762.19 |
DisclosureSEC source: 0001193125-26-055442 · ownership.xml · nonDerivative · entry 1 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 452,415 F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.6075 to $0.671. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 354,250 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 23:02 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 952,250 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001193125-26-039760 · ownership.xml · derivative · entry 2 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 952,250 Underlying: Common Stock · 952,250 shares Expires 2036-02-02 F4 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 23:02 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantCommon Stock | 158,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-039760 · ownership.xml · nonDerivative · entry 1 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 458,266 F1 · security: Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on August 15, 2026, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested. F3 · balance_after: Includes 369,875 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 01:33 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 3,126 | $1.33 | $4,157.58 |
DisclosureSEC source: 0001193125-25-284996 · ownership.xml · nonDerivative · entry 1 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 299,666 F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 6, 2025. F2 · balance_after: Includes 211,275 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 00:58 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 4,920 | $1.25 | $6,164.76 |
DisclosureSEC source: 0001667937-25-000006 · ownership.xml · nonDerivative · entry 3 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 302,792 F6 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 6, 2025. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.18 to $1.32. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F7 · balance_after: Includes 219,881 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 00:58 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 3,893 | $1.25 | $4,877.93 |
DisclosureSEC source: 0001667937-25-000006 · ownership.xml · nonDerivative · entry 2 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 307,712 F4 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.18 to $1.32. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F5 · balance_after: Includes 233,318 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 00:58 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 5,720 | $1.25 | $7,167.16 |
DisclosureSEC source: 0001667937-25-000006 · ownership.xml · nonDerivative · entry 1 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 311,605 F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.18 to $1.32. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 243,943 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 16, 2025 Filed May 16, 2025 23:07 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 3,189 | $0.44 | $1,411.77 |
DisclosureSEC source: 0000950170-25-073823 · ownership.xml · nonDerivative · entry 1 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 317,325 F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 6, 2025. F2 · balance_after: Includes 259,568 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 01:42 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 3,947 | $0.54 | $2,125.06 |
DisclosureSEC source: 0000950170-25-036770 · ownership.xml · nonDerivative · entry 2 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,514 F4 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.5080 to $0.5846. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F5 · balance_after: Includes 268,174 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 01:42 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 5,794 | $0.54 | $3,119.49 |
DisclosureSEC source: 0000950170-25-036770 · ownership.xml · nonDerivative · entry 1 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 324,461 F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.5080 to $0.5846. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 278,799 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 06, 2025 Filed Feb 8, 2025 01:29 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to Buy) · Derivative | 401,390 | Not disclosed Strike: $1.21 | Not disclosed |
DisclosureSEC source: 0000950170-25-016582 · ownership.xml · derivative · entry 9 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 401,390 Underlying: Common Stock · 401,390 shares Expires 2032-02-14 F8 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on February 6, 2025 (the "Effective Date"). The Option Repricing applies to nonstatutory options with exercise prices greater than $5.25 per share held by Reporting Person as of the Effective Date. F9 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $1.21 per share. However, if the Reporting Person exercises a repriced option before the end of a "Retention Period" that begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) July 24, 2025 or (ii) a Change in Control, as defined in the Issuer's 2021 Equity Incentive Plan, then the Reporting Person will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. F11 · derivative.exercise_date: 1/48th of the shares underying the option vested on March 15, 2022, and the remaining shares vest in 48 equal monthly installments thereafter. Read SEC document |
| February 06, 2025 Filed Feb 8, 2025 01:29 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | Disposition to issuerStock Option (Right to Buy) · Derivative | 401,390 | Not disclosed Strike: $15.19 | Not disclosed |
DisclosureSEC source: 0000950170-25-016582 · ownership.xml · derivative · entry 8 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 401,390 shares Expires 2032-02-14 F8 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on February 6, 2025 (the "Effective Date"). The Option Repricing applies to nonstatutory options with exercise prices greater than $5.25 per share held by Reporting Person as of the Effective Date. F9 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $1.21 per share. However, if the Reporting Person exercises a repriced option before the end of a "Retention Period" that begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) July 24, 2025 or (ii) a Change in Control, as defined in the Issuer's 2021 Equity Incentive Plan, then the Reporting Person will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. F11 · derivative.exercise_date: 1/48th of the shares underying the option vested on March 15, 2022, and the remaining shares vest in 48 equal monthly installments thereafter. Read SEC document |
| February 06, 2025 Filed Feb 8, 2025 01:29 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to Buy) · Derivative | 161,214 | Not disclosed Strike: $1.21 | Not disclosed |
DisclosureSEC source: 0000950170-25-016582 · ownership.xml · derivative · entry 7 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,214 Underlying: Common Stock · 161,214 shares Expires 2031-06-16 F8 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on February 6, 2025 (the "Effective Date"). The Option Repricing applies to nonstatutory options with exercise prices greater than $5.25 per share held by Reporting Person as of the Effective Date. F9 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $1.21 per share. However, if the Reporting Person exercises a repriced option before the end of a "Retention Period" that begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) July 24, 2025 or (ii) a Change in Control, as defined in the Issuer's 2021 Equity Incentive Plan, then the Reporting Person will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. F10 · derivative.exercise_date: 1/48th of the shares underying the option vested on July 17, 2021, and the remaining shares vest in 48 equal monthly installments thereafter. Read SEC document |
| February 06, 2025 Filed Feb 8, 2025 01:29 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | Disposition to issuerStock Option (Right to Buy) · Derivative | 161,214 | Not disclosed Strike: $9.36 | Not disclosed |
DisclosureSEC source: 0000950170-25-016582 · ownership.xml · derivative · entry 6 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 161,214 shares Expires 2031-06-16 F8 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on February 6, 2025 (the "Effective Date"). The Option Repricing applies to nonstatutory options with exercise prices greater than $5.25 per share held by Reporting Person as of the Effective Date. F9 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $1.21 per share. However, if the Reporting Person exercises a repriced option before the end of a "Retention Period" that begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) July 24, 2025 or (ii) a Change in Control, as defined in the Issuer's 2021 Equity Incentive Plan, then the Reporting Person will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. F10 · derivative.exercise_date: 1/48th of the shares underying the option vested on July 17, 2021, and the remaining shares vest in 48 equal monthly installments thereafter. Read SEC document |
| February 06, 2025 Filed Feb 8, 2025 01:29 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to Buy) · Derivative | 353,271 | Not disclosed Strike: $1.21 | Not disclosed |
DisclosureSEC source: 0000950170-25-016582 · ownership.xml · derivative · entry 5 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 353,271 Underlying: Common Stock · 353,271 shares Expires 2031-02-26 F8 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on February 6, 2025 (the "Effective Date"). The Option Repricing applies to nonstatutory options with exercise prices greater than $5.25 per share held by Reporting Person as of the Effective Date. F9 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $1.21 per share. However, if the Reporting Person exercises a repriced option before the end of a "Retention Period" that begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) July 24, 2025 or (ii) a Change in Control, as defined in the Issuer's 2021 Equity Incentive Plan, then the Reporting Person will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. F7 · derivative.exercise_date: The shares underlying the option are fully vested and exercisable. Read SEC document |
| February 06, 2025 Filed Feb 8, 2025 01:29 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | Disposition to issuerStock Option (Right to Buy) · Derivative | 353,271 | Not disclosed Strike: $5.64 | Not disclosed |
DisclosureSEC source: 0000950170-25-016582 · ownership.xml · derivative · entry 4 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 353,271 shares Expires 2031-02-26 F8 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on February 6, 2025 (the "Effective Date"). The Option Repricing applies to nonstatutory options with exercise prices greater than $5.25 per share held by Reporting Person as of the Effective Date. F9 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $1.21 per share. However, if the Reporting Person exercises a repriced option before the end of a "Retention Period" that begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) July 24, 2025 or (ii) a Change in Control, as defined in the Issuer's 2021 Equity Incentive Plan, then the Reporting Person will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. F7 · derivative.exercise_date: The shares underlying the option are fully vested and exercisable. Read SEC document |
| February 06, 2025 Filed Feb 8, 2025 01:29 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 650,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0000950170-25-016582 · ownership.xml · derivative · entry 3 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2035-03-05 F6 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested. Read SEC document |
| February 06, 2025 Filed Feb 8, 2025 01:29 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantCommon Stock | 34,424 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-016582 · ownership.xml · nonDerivative · entry 2 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,255 F1 · security: Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock. F4 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the total number of shares subject to the restricted stock unit award on May 15, 2025, and 1/4th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested. F5 · balance_after: Includes 294,424 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 06, 2025 Filed Feb 8, 2025 01:29 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantCommon Stock | 107,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-016582 · ownership.xml · nonDerivative · entry 1 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 295,831 F1 · security: Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on August 15, 2025, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested. F3 · balance_after: Includes 260,000 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 16, 2024 Filed Aug 17, 2024 00:25 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 3,946 | $2.89 | $11,421.70 |
DisclosureSEC source: 0000950170-24-098234 · ownership.xml · nonDerivative · entry 2 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,331 F4 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.79 to $3.02. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 152,500 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 16, 2024 Filed Aug 17, 2024 00:25 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 5,802 | $2.89 | $16,793.89 |
DisclosureSEC source: 0000950170-24-098234 · ownership.xml · nonDerivative · entry 1 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,277 F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.79 to $3.02. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 152,500 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 23, 2024 Filed Feb 28, 2024 00:28 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 505,000 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0000950170-24-021546 · ownership.xml · derivative · entry 2 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 505,000 Underlying: Common Stock · 505,000 shares Expires 2034-02-22 F4 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested. Read SEC document |
| February 23, 2024 Filed Feb 28, 2024 00:28 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantCommon Stock | 85,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-021546 · ownership.xml · nonDerivative · entry 1 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,079 F1 · security: Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on August 15, 2024, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested. F3 · balance_after: Includes 178,750 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 16, 2024 Filed Feb 17, 2024 01:30 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 6,358 | $5.86 | $37,257.88 |
DisclosureSEC source: 0000950170-24-016664 · ownership.xml · nonDerivative · entry 1 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,079 F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $5.61 to $6.15. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 93,750 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 22:31 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 5,563 | $3.81 | $21,195.03 |
DisclosureSEC source: 0001209191-23-046639 · doc4.xml · nonDerivative · entry 1 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,437 F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $3.76 to $3.87. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 109,375 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 23:43 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 675,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001209191-23-010880 · doc4.xml · derivative · entry 2 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 675,000 Underlying: Common Stock · 675,000 shares Expires 2033-02-14 F4 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 23:43 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-010880 · doc4.xml · nonDerivative · entry 1 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 F1 · security: Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on the six month anniversary of the Transaction Date, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested. F3 · balance_after: Includes 125,000 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 22:45 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 401,390 | $0.00 Strike: $15.19 | $0.00 |
DisclosureSEC source: 0001209191-22-010925 · doc4.xml · derivative · entry 1 Ali Faraz · CIK 0001667937 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,390 Underlying: Common Stock · 401,390 shares Expires 2032-02-14 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one (1) month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 22:01 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 25,200 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0000899243-17-000698 · doc4.xml · derivative · entry 1 Ali Faraz · CIK 0001667937 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,200 Underlying: Common Stock · 25,200 shares Expires 2027-01-03 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following 1/4/2018 while the optionee provides continuous service to the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.